Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)

niversity of Queensland0 个研究点目标入组 720 人开始时间: 2022年3月29日最近更新: 2024年7月15日

适应症

试验速览

暂无简介。

•Children (<18 years) with an oncological or malignant haematological condition who have a CVAD in situ (including peripherally inserted central catheters [PICCs], tunnelled (cuffed or non-cuffed) [e.g. Hickman®; Becton Dickinson, US] and totally implanted [e.g. PORT-A-CATH®; Smith Medical, US] will be eligible for inclusion. ; Children (<18 years) with an oncological or malignant haematological condition who have a CVAD in situ (including peripherally inserted central catheters [PICCs], tunnelled (cuffed or non-cuffed) [e.g. Hickman®; Becton Dickinson, US] and totally implanted [e.g. PORT-A-CATH®; Smith Medical, US] will be eligible for inclusion.

•-End-of-life pathway/measures at recruitment
•-Pre-existing coagulopathic condition not related to current diagnosis or treatment (e.g. Haemophilia A and B or other factor deficiency; Immune Thrombocytopenic Purpura (ITP); Von Willebrand’s disease)
•-Known allergy to heparin or T-EDTA
•; -End-of-life pathway/measures at recruitment
•-Pre-existing coagulopathic condition not related to current diagnosis or treatment (e.g. Haemophilia A and B or other factor deficiency; Immune Thrombocytopenic Purpura (ITP); Von Willebrand’s disease)
•-Known allergy to heparin or T-EDTA

发起方

niversity of Queensland